|
|
lncRNA影响乳腺癌化疗耐药性的研究进展
|
Abstract:
目前lncRNA对乳腺癌化疗耐药的相关研究越来越多，本文重点就lncRNA对乳腺癌常见化疗药耐药的发生和发展中起的重要作用进行总结，并对lncRNA与乳腺癌化疗耐药之间的作用进行分析综合，讨论lncRNA作为乳腺癌化疗耐药的潜在靶点的治疗意义。本文总结国内外文献对lncRNA与乳腺癌一线化疗药物紫杉醇、多西他赛、阿霉素和顺铂的耐药相关研究进行综述。lncRNA介导乳腺癌化疗耐药的耐药机制包括：(1) 影响化疗药物靶基因的lncRNA及其影响效应。(2) lncRNAs通过调节乳腺癌细胞周期和细胞凋亡。(3) lncRNAs靶向PTE、NF-κB等信号通路。(4) lncRNAs影响多重耐药基因。lncRNA有望是改善乳腺癌患者化疗耐药的新靶点。以lncRNA为靶点可能是未来改善乳腺癌患者化疗效果的一种新策略。
At present, there are more and more researches on lncRNA in breast cancer chemotherapy resistance. This article focuses on the important role of lncRNA in the occurrence and development of common chemotherapy drug resistance in breast cancer, and analyzes and synthefies the role between lncRNA and breast cancer chemotherapy resistance to discuss the therapeutic significance of lncRNA as a potential target for chemoresistance in breast cancer. In this paper, the domestic and foreign literature on the relationship between lncRNA and the resistance of first-line chemotherapy drugs paclitaxel, docetaxel, doxorubicin and cisplatin in breast cancer is reviewed. The mechanisms of lncRNA-mediated chemoresistance in breast cancer include: (1) lncRNA affects the target genes of chemotherapy drugs and its effect, (2) lncRNAs regulate breast cancer cell cycle and apoptosis, (3) lncRNAs target PTE and NF-κB signaling pathways, (4) lncRNAs affect multidrug resistance genes. lncRNA is expected to be a new target for improving chemotherapy resistance in breast cancer patients. Targeting lncRNA may be a new strategy to improve the efficacy of chemotherapy in breast cancer patients in the future.
| [1] | Loibl, S., Poortmans, P., Morrow, M., Denkert, C. and Curigliano, G. (2021) Breast Cancer. Lancet, 397, 1750-1769. https://doi.org/10.1016/S0140-6736(20)32381-3 |
| [2] | Dan, V.M., Raveendran, R.S. and Baby, S. (2021) Resistance to Intervention: Paclitaxel in Breast Cancer. Mini-Reviews in Medicinal Chemistry, 21, 1237-1268. https://doi.org/10.2174/1389557520999201214234421 |
| [3] | Lin, W., Zhou, Q., Wang, C.Q., Zhu, L., Bi, C., Zhang, S., Wang, X. and Jin, H. (2020) lncRNAs Regulate Metabolism in Cancer. International Journal of Biological Sciences, 16, 1194-1206. https://doi.org/10.7150/ijbs.40769 |
| [4] | Qian, X., Zhao, J., Yeung, P.Y., Zhang, Q.C. and Kwok, C.K. (2019) Revealing lncRNA Structures and Interactions by Sequencing-Based Approaches. Trends in Biochemical Sciences, 44, 33-52. https://doi.org/10.1016/j.tibs.2018.09.012 |
| [5] | Peng, L., Jiang, J., Tang, B., Nice, E.C., Zhang, Y.Y. and Xie, N. (2020) Managing Therapeutic Resistance in Breast Cancer: From the lncRNAs Perspective. Theranostics, 10, 10360-10377. https://doi.org/10.7150/thno.49922 |
| [6] | Zhang, X. and Yang, H. (2020) Research Progress on Long Non-Coding RNAs and Drug Resistance of Breast Cancer. Clinical Breast Cancer, 20, 275-282. https://doi.org/10.1016/j.clbc.2019.11.001 |
| [7] | Zeng, Y., Wang, G., Zhou, C.F., Zhang, H.B., Sun, H., Zhang, W., Zhou, H.H., Liu, R. and Zhu, Y.S. (2019) lncRNA Profile Study Reveals a Three-lncRNA Signature Associated with the Pathological Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer. Frontiers in Pharmacology, 10, Article 574. https://doi.org/10.3389/fphar.2019.00574 |
| [8] | Pan, Y., Pan, Y., Cheng, Y., Yang, F., Yao, Z. and Wang, O. (2018) Knockdown of lncRNA MAPT-AS1 Inhibites Proliferation and Migration and Sensitizes Cancer Cells to Paclitaxel by Regulating MAPT Expression in ER-Negative Breast Cancers. Cell & Bioscience, 8, Article No. 7. https://doi.org/10.1186/s13578-018-0207-5 |
| [9] | Wang, R., Zhang, T., Yang, Z., Jiang, C. and Seng, J. (2018) Long Non-Coding RNA FTH1P3 Activates Paclitaxel Resistance in Breast Cancer through MiR-206/ABCB1. Journal of Cellular and Molecular Medicine, 22, 4068-4075. https://doi.org/10.1111/jcmm.13679 |
| [10] | Chang, L., Hu, Z., Zhou, Z. and Zhang, H. (2018) Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer. Cellular Physiology and Biochemistry, 48, 16-28. https://doi.org/10.1159/000491659 |
| [11] | Li, Y., Wang, Y., Wang, H., Zhang, L., Ding, Y., Chen, S., Yang, Q. and Chen, C. (2017) [Effects of lncRNA RP11-770J1.3 and TMEM25 Expression on Paclitaxel Resistance in Human Breast Cancer Cells]. Journal of Zhejiang University, 46, 364-370. |
| [12] | Zheng, S., Fu, W., Huang, Q., Zhou, J., Lu, K., Gu, J., Ma, R. and Guo, G. (2023) lncRNA PRKCQ-AS1 Regulates Paclitaxel Resistance in Triple-Negative Breast Cancer Cells Through MiR-361-5p/PIK3C3 Mediated Autophagy. Clinical and Experimental Pharmacology and Physiology, 50, 431-442. https://doi.org/10.1111/1440-1681.13758 |
| [13] | Zhang, H., Zhao, B., Wang, X., Zhang, F. and Yu, W. (2019) LINC00511 Knockdown Enhances Paclitaxel Cytotoxicity in Breast Cancer via Regulating MiR-29c/CDK6 Axis. Life Sciences, 228, 135-144. https://doi.org/10.1016/j.lfs.2019.04.063 |
| [14] | Zheng, P., Dong, L., Zhang, B., Dai, J., Zhang, Y., Wang, Y. and Qin, S. (2019) Long Noncoding RNA CASC2 Promotes Paclitaxel Resistance in Breast Cancer through Regulation of MiR-18a-5p/CDK19. Histochemistry and Cell Biology, 152, 281-291. https://doi.org/10.1007/s00418-019-01794-4 |
| [15] | Liu, C., Jiang, F., Zhang, X. and Xu, X. (2020) Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via MiR-613/CDK12 Axis. Cancer Management and Research, 12, 2777-2788. https://doi.org/10.2147/CMAR.S241969 |
| [16] | Shin, V.Y., Chen, J., Cheuk, I.W., Siu, M.T., Ho, C.W., Wang, X., Jin, H. and Kwong, A. (2019) Long Non-Coding RNA NEAT1 Confers Oncogenic Role in Triple-Negative Breast Cancer through Modulating Chemoresistance and Cancer Stemness. Cell Death & Disease, 10, Article No. 270. https://doi.org/10.1038/s41419-019-1513-5 |
| [17] | Gu, M., Zheng, W., Zhang, M., Dong, X., Zhao, Y., Wang, S., Jiang, H. and Zheng, X. (2020) lncRNA NONHSAT141924 Promotes Paclitaxel Chemotherapy Resistance through P-CREB/Bcl-2 Apoptosis Signaling Pathway in Breast Cancer. Journal of Cancer, 11, 3645-3654. https://doi.org/10.7150/jca.39463 |
| [18] | Si, X., Zang, R., Zhang, E., Liu, Y., Shi, X., Zhang, E., Shao, L., Li, A., Yang, N., Han, X., et al. (2016) lncRNA H19 Confers Chemoresistance in ERalpha-Positive Breast Cancer through Epigenetic Silencing of the Pro-Apoptotic Gene BIK. Oncotarget, 7, 81452-81462. https://doi.org/10.18632/oncotarget.13263 |
| [19] | Li, P.P., Li, R.G., Huang, Y.Q., Lu, J.P., Zhang, W.J. and Wang, Z.Y. (2021) lncRNA OTUD6B-AS1 Promotes Paclitaxel Resistance in Triple Negative Breast Cancer by Regulation of MiR-26a-5p/MTDH Pathway-Mediated Autophagy and Genomic Instability. Aging, 13, 24171-24191. https://doi.org/10.18632/aging.203672 |
| [20] | Zhao, T., Zhang, T., Zhang, Y., Zhou, B. and Lu, X. (2022) Paclitaxel Resistance Modulated by the Interaction between TRPS1 and AF178030.2 in Triple-Negative Breast Cancer. Evidence-Based Complementary and Alternative Medicine, 2022, Article ID: 6019975. https://doi.org/10.1155/2022/6019975 |
| [21] | Gligorov, J. and Lotz, J.P. (2004) Preclinical Pharmacology of the Taxanes: Implications of the Differences. Oncologist, 9, 3-8. https://doi.org/10.1634/theoncologist.9-suppl_2-3 |
| [22] | Huang, P., Li, F., Li, L., You, Y., Luo, S., Dong, Z., Gao, Q., Wu, S., Brunner, N. and Stenvang, J. (2018) lncRNA Profile Study Reveals the MRNAs and lncRNAs Associated with Docetaxel Resistance in Breast Cancer Cells. Scientific Reports, 8, Article No. 17970. https://doi.org/10.1038/s41598-018-36231-4 |
| [23] | Li, J., Ke, J., Qin, C.L. and Zhu, X. (2022) LINC00680 Modulates Docetaxel Resistance in Breast Cancer via the MiR-320b/CDKL5 Axis. International Journal of Immunopathology and Pharmacology, 36, 1-9. https://doi.org/10.1177/03946320221105608 |
| [24] | Li, J., Kang, J., Liu, W., Liu, J., Pan, G., Mao, A., Zhang, Q., Lu, J., Ding, J. and Li, H. (2022) Docetaxel-Resistant Triple-Negative Breast Cancer Cell-Derived Exosomal lncRNA LINC00667 Reduces the Chemosensitivity of Breast Cancer Cells to Docetaxel via Targeting MiR-200b-3p/Bcl-2 Axis. European Journal of Histochemistry, 66, 3592. https://doi.org/10.4081/ejh.2022.3529 |
| [25] | Zhang, C., Wang, J., Zhang, J., Qu, H. and Tang, X. (2020) LINC00461 Overexpression Can Induce Docetaxel Resistance in Breast Cancer by Interacting with MiR-411-5p. OncoTargets and Therapy, 13, 5551-5562. https://doi.org/10.2147/OTT.S247776 |
| [26] | Ning, X., Zhao, J., He, F., Yuan, Y., Li, B. and Ruan, J. (2021) Long Non-Coding RNA TMPO-AS1 Facilitates Chemoresistance and Invasion in Breast Cancer by Modulating the MiR-1179/TRIM37 Axis. Oncology Letters, 22, Article No. 500. https://doi.org/10.3892/ol.2021.12761 |
| [27] | Zhang, Z., Yu, X., Yu, X., Wang, Z., Wu, P. and Huang, J. (2015) Anthracyclines Potentiate Anti-Tumor Immunity: A New Opportunity for Chemoimmunotherapy. Cancer Letters, 369, 331-335. https://doi.org/10.1016/j.canlet.2015.10.002 |
| [28] | Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. and Gianni, L. (2004) Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacological Reviews, 56, 185-229. https://doi.org/10.1124/pr.56.2.6 |
| [29] | Yao, N., Fu, Y., Chen, L., Liu, Z., He, J., Zhu, Y., et al. (2019) Long Non-Coding RNA NONHSAT101069 Promotes Epirubicin Resistance, Migration, and Invasion of Breast Cancer Cells through NONHSAT101069/MiR-129-5p/Twist1 Axis. Oncogene, 38, 7216-7233. https://doi.org/10.1038/s41388-019-0904-5 |
| [30] | Gooding, A.J., Zhang, B., Gunawardane, L., Beard, A., Valadkhan, S. and Schiemann, W.P. (2019) The lncRNA BORG Facilitates the Survival and Chemoresistance of Triple-Negative Breast Cancers. Oncogene, 38, 2020-2041. https://doi.org/10.1038/s41388-018-0586-4 |
| [31] | Chen, Z., Pan, T., Jiang, D., Jin, L., Geng, Y., Feng, X., et al. (2020) The lncRNA-GAS5/MiR-221-3p/DKK2 Axis Modulates ABCB1-Mediated Adriamycin Resistance of Breast Cancer via the Wnt/β-Catenin Signaling Pathway. Nucleic Acids, 19, 1434-1448. https://doi.org/10.1016/j.omtn.2020.01.030 |
| [32] | He, D.X., Zhang, G.Y., Gu, X.T., Mao, A.Q., Lu, C.X., Jin, J., Liu, D.Q. and Ma, X. (2016) Genome-Wide Profiling of Long Non-Coding RNA Expression Patterns in Anthracycline-Resistant Breast Cancer Cells. International Journal of Oncology, 49, 1695-1703. https://doi.org/10.3892/ijo.2016.3665 |
| [33] | O’Brien, K.M., Cole, S.R., Tse, C.K., Perou, C.M., Carey, L.A., Foulkes, W.D., Dressler, L.G., Geradts, J. and Millikan, R.C. (2010) Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study. Clinical Cancer Research, 16, 6100-6110. https://doi.org/10.1158/1078-0432.CCR-10-1533 |
| [34] | Adriaens, C., Standaert, L., Barra, J., Latil, M., Verfaillie, A., Kalev, P., Boeckx, B., Wijnhovwn, P.W., Radaelli, E., Vwemi, W., et al. (2016) P53 Induces Formation of NEAT1 lncRNA-Containing Paraspeckles That Modulate Replication Stress Response and Chemosensitivity. Nature Medicine, 22, 861-868. https://doi.org/10.1038/nm.4135 |
| [35] | Zhang, M., Yang, L., Hou, L. and Tang, X. (2021) lncRNA SNHG1 Promotes Tumor Progression and Cisplatin Resistance through Epigenetically Silencing MiR-381 in Breast Cancer. Bioengineered, 12, 9239-9250. https://doi.org/10.1080/21655979.2021.1996305 |
| [36] | Du, C., Wang, Y., Zhang, Y., Zhang, J., Zhang, L. and Li, J. (2020) lncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-Negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis. Cell Transplantation, 29, 1-11. https://doi.org/10.1177/0963689720929983 |
| [37] | Wu, J., Chen, H., Ye, M., Wang, B., Zhang, Y., Sheng, J., Meng, T. and Chen, H. (2019) Long Noncoding RNA HCP5 Contributes to Cisplatin Resistance in Human Triple-Negative Breast Cancer via Regulation of PTEN Expression. Biomedicine & Pharmacotherapy, 115, Article ID: 108869. https://doi.org/10.1016/j.biopha.2019.108869 |
